The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | Is immunotherapy cost-effective?
One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether it is cost-effective for patients to receive monoclonal antibody therapy. Dr Fonseca then states that pharmacoeconomic analyses are much more complex than most people consider. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
